Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery | Zendy

Matthieu Grégoire | Zendy; Julia Brochard Libois | Zendy; D. Waast | Zendy; Benjamin Gaborit | Zendy; Marc Dauty | Zendy; Guillaume Deslandes | Zendy; Éric Dailly | Zendy; S. Touchais | Zendy; D. Boutoille | Zendy; Nicolas Grégoire | Zendy; William Couet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Author(s) -

Matthieu Grégoire,

Julia Brochard Libois,

D. Waast,

Benjamin Gaborit,

Marc Dauty,

Guillaume Deslandes,

Éric Dailly,

S. Touchais,

D. Boutoille,

Nicolas Grégoire,

William Couet

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02432-17

Subject(s) - liter , pharmacokinetics , medicine , plasma concentration , gastric bypass , weight loss , surgery , obesity , gastroenterology

An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC0–24 ) was 28.3 mg/liter · h. The AUC0–24 /MIC ratio for unbound concentrations and for sensitiveStaphylococcus andStreptococcus strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research